Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Sales of Investments

Cash received from selling or redeeming investments.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments declines year over year

Q3 FY2026 sales of investments of $57M fell 52.5% year over year, behind the -41.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 6.6% from the prior quarter. Over 3 fiscal years it compounded at -8.5% a year.

Context

  • Sales of investments amounted to 151.8% of revenue in FY2025, down 109.1 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -52.5% toward the trailing-twelve-month pace of -41.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$57M-6.6% QoQ
Last fiscal yearDec 2025
$400M-6.5% YoY
LTMSep 2026
$262M-41.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.5%——
1 year-6.5%——
3-year CAGR-8.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
400M USD
Year-over-year change
-6.5%
4-year CAGR
-14.9%

Sales of Investments vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -41.3% is the 7th highest of 10, against a peer median of -19.6%.
  • Sales of investments amounts to 69.1% of revenue for IOVA, versus a peer median of 205.1%.
IOVA Competitors
Sales of Investments for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€10.31B EUR-19.6%+189.9%389.9%
GMABGenmab A/SLTM Jun 2026$2.03B USD—-28.7%49.1%
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
IBRXImmunityBio, Inc.LTM Sep 2026$374.39M USD+1501.0%—205.1%
REPLReplimune Group, Inc.LTM Dec 2025$367.56M USD-19.2%+14.7%—
FATEFate Therapeutics, Inc.LTM Mar 2026$271.96M USD-14.9%-19.9%4305.9%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$262M USD-41.3%-8.5%69.1%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$110.41M USD-38.6%-2.0%—
IMNMImmunome, Inc.LTM Sep 2026$54M USD-81.1%——
STTKShattuck Labs, Inc.LTM Mar 2026$43.92M USD-54.1%-43.1%4391.5%
IMCRImmunocore Holdings plcLTM Mar 2026$13.99M USD+39.9%—3.6%
Peer median (excluding IOVA) —-19.6%-2.0%205.1%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
Deferred Income Tax00(3.48M)(2.83M)(2.07M)
Stock-Based Compensation69.77M84.02M62.63M109.63M61.58M
Change in Working Capital24.55M(2.89M)(6.52M)(122.56M)(24.27M)
Accounts Receivables00(149K)(69.19M)(13.11M)
Inventory00(10.12M)(39.92M)(14.21M)
Accounts Payables6.98M5.88M4.83M(7.84M)(6.66M)
Other Working Capital17.58M(8.78M)(1.08M)(5.61M)9.71M
Other Non-Cash Items6.01M871K(3.54M)(8.65M)6.01M
Operating Cash Flow(227.94M)(292.76M)(361.82M)(352.98M)(302.41M)
Capital Expenditures(37.57M)(20.43M)(22.29M)(11.07M)(33.84M)
Acquisitions (Net)(37.71M)(276.88M)(212.63M)(52.57M)0
Purchases of Investments(725.21M)(245.82M)(205.9M)(460.77M)(318.67M)
Sales of Investments762.91M522.7M285.58M428M400M
Other Investing Activities37.71M276.88M000
Investing Cash Flow132K256.46M(155.24M)(96.41M)47.5M
Debt Repayment1M0000
Common Stock Issued203.16M189.5M463.28M397.3M306.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities35.11M648K(322K)(6.64M)(7.06M)
Financing Cash Flow239.27M190.15M462.96M390.66M300.77M
Effect of Forex Changes00(2.74M)(541K)1.52M
Net Change in Cash11.46M153.85M(56.84M)(59.27M)47.38M
Free Cash Flow(265.52M)(313.18M)(384.11M)(364.05M)(336.24M)

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.